Grant: Team Grant: Alzheimer's Disease France-Quebec
Université Laval
$60,000.00
MicroARNS comme modulateurs de la pathologie Tau
FY 2009-10
Summary
Thirty five millon people worldwide are estimated to be living with Alzheimer’s disease and related dementia. This number is expected to double every 20 years. Alzheimer’s disease represents 70% of demented disorders. Others include Lewy body dementia, vascular dementia and tauopathies such as frontotemporal dementia and progressive aphasia. Tauopathies are a group of dementing disorders characterized by Tau pathology. In Alzheimer’s disease, microtubule-associated protein Tau is the major component of paired helical filaments inside degenerating neurons referred to as neurofibrillary tangles (NFTs). However, aggregation of Tau inside neurons or glial cells is observed in more than twenty neurological disorders, which together form the so-called Tauopathies. For instance, the Tau / MAPT gene locus is associated with the development of frontotemporal dementia. In some of the patients, Tau pathology may be related to early changes in tau alternative splicing. When aggregated, one of the major questions that to be answered is whether there is a loss or gain of toxic functions of Tau. Recent development of transgenic animal models may be useful to address this question. NFTs seem to be of a lesser importance since they represent end-stages of aggregation. In contrast, it has been proposed that the real toxic entity is misfolded non-aggregated tau. Indeed, turning off the expression of the human tau transgene in a mouse model with repressible expression of tau, reverses memory defects even if NFTs continue to accumulate. Likewise, in mouse tauopathy models various pathologies become apparent, including activated microglia and behavioural deficits, before the appearance of NFTs. Therefore, NFTs are neither necessary nor sufficient to cause a cognitive decline. These results altogether do not completely rule out a possible role of tangles in neurodegeneration; however, the memory decline induced in relationship with tau pathology, particularly during the earliest, pre-symptomatic stages of dementia, most probably relies on unknown mechanisms. Among new mechanisms involved in neurodegeneration in AD and related disorders, micro RNAs are of particular interest. miRNAs are a class of conserved noncoding RNAs, which depend on the RNAi machinery. Recent data have shown that they have a role in learning-related synaptic plasticity and brain functioning.
The present project aims to understand the relationships between mRNAs and Tau pathology. Its scope is widened to all tauopathies and not only AD. It also explains why we are focussing on the Tau side of the pathology. The strength of the project is the synergy and complementary of two research laboratories (one Canadian, specialized in miRNAs in neurodegenerative disorders and one expert in neurofibrillary degeneration in Alzheimer and Tauopathies in France) with promising preliminary data. The double approach is original and hopeful for diagnosis and new innovative therapeutic strategies.
Department
Program
Team Grant: Alzheimer's Disease France-Quebec
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
205240
Name
Hébert Sébastien
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Fonds de recherche du Québec - Santé (FRQS); The French National Research Agency (France)
Prcname2
Special Cases
Projecttitle
MicroARNS comme modulateurs de la pathologie Tau
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
Team Grant: Alzheimer's Disease France-Quebec
Keyworddelim
Alternative Splicing; Alzheimer'S Disease; Animal Models; Dicer; Phosphorylation; Tauopathies
Abstract
Thirty five millon people worldwide are estimated to be living with Alzheimer’s disease and related dementia. This number is expected to double every 20 years. Alzheimer’s disease represents 70% of demented disorders. Others include Lewy body dementia, vascular dementia and tauopathies such as frontotemporal dementia and progressive aphasia. Tauopathies are a group of dementing disorders characterized by Tau pathology. In Alzheimer’s disease, microtubule-associated protein Tau is the major component of paired helical filaments inside degenerating neurons referred to as neurofibrillary tangles (NFTs). However, aggregation of Tau inside neurons or glial cells is observed in more than twenty neurological disorders, which together form the so-called Tauopathies. For instance, the Tau / MAPT gene locus is associated with the development of frontotemporal dementia. In some of the patients, Tau pathology may be related to early changes in tau alternative splicing. When aggregated, one of the major questions that to be answered is whether there is a loss or gain of toxic functions of Tau. Recent development of transgenic animal models may be useful to address this question. NFTs seem to be of a lesser importance since they represent end-stages of aggregation. In contrast, it has been proposed that the real toxic entity is misfolded non-aggregated tau. Indeed, turning off the expression of the human tau transgene in a mouse model with repressible expression of tau, reverses memory defects even if NFTs continue to accumulate. Likewise, in mouse tauopathy models various pathologies become apparent, including activated microglia and behavioural deficits, before the appearance of NFTs. Therefore, NFTs are neither necessary nor sufficient to cause a cognitive decline. These results altogether do not completely rule out a possible role of tangles in neurodegeneration; however, the memory decline induced in relationship with tau pathology, particularly during the earliest, pre-symptomatic stages of dementia, most probably relies on unknown mechanisms. Among new mechanisms involved in neurodegeneration in AD and related disorders, micro RNAs are of particular interest. miRNAs are a class of conserved noncoding RNAs, which depend on the RNAi machinery. Recent data have shown that they have a role in learning-related synaptic plasticity and brain functioning.
The present project aims to understand the relationships between mRNAs and Tau pathology. Its scope is widened to all tauopathies and not only AD. It also explains why we are focussing on the Tau side of the pathology. The strength of the project is the synergy and complementary of two research laboratories (one Canadian, specialized in miRNAs in neurodegenerative disorders and one expert in neurofibrillary degeneration in Alzheimer and Tauopathies in France) with promising preliminary data. The double approach is original and hopeful for diagnosis and new innovative therapeutic strategies.
Competitiondate
201001
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hébert, Sébastien; Buee, Luc
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Neurosc Mental Hlth &A~ $20,000~ $0~Institute of Aging~ $20,000~ $0~~ $20,000~ $0~